Startseite
Impressum
Datenschutz
 
Volume 38, 11 May 2007 5/2007
 
  NEW ON THE MARKET
 

New therapeutic strategy in type 2 diabetes mellitus: incretin mimetic exenatide (BYETTA)
Bupropion (ELONTRIL) for depression

 
  THERAPY FROM A CRITICAL VIEWPOINT
 

Jikei Heart-study with valsartan: advantage only because of open design?
Coronary angioplasty without effect on prognosis of stable angina

 
  a-t READERS' QUESTIONS AND COMMENTS
 

Herpes zoster: brivudine (ZOSTEX) better than aciclovir (ZOVIRAX)?
Smoking and COLD: the definition of "pack-years"

 
  IN BRIEF
 

No approval of the cox-2-inhibitor etoricoxib (ARCOXIA) in the US
Adjuvanted influenza vaccine FLUAD: no proven relevant clinical advantage

 
  CURRENT ADR NETWORK REPORT

Does clopidogrel (PLAVIX, ISCOVER) worsen psoriasis?

 
  SIDE EFFECTS
 

Valvular heart disease: measures taken against ergoline dopamine agonists
About the risk for hip fracture due to proton pump inhibitors
Postmenopausal osteoporosis: atrial fibrillation due to bisphosphonates?
Desmopressin (e.g. MINIRIN) - nasal spray not for enuresis nocturna

 
© arznei-telegramm 5/2007